Disease progression after discontinuation of corticosteroid treatment in a COVID-19 patient with ARDS  

作　　者：Lam Nguyen-Ho 

机构地区：[1]Department of Internal Medicine,University of Medicine and Pharmacy at Ho Chi Minh City,Vietnam [2]University Medical Center HCMC,Ho Chi Minh City,Vietnam

出　　处：《Asian Pacific Journal of Tropical Medicine》2022年第1期47-48,共2页亚太热带医药杂志（英文版）

摘　　要：Excessive acute inflammatory response in coronavirus-induced disease 2019(COVID-19)patients results in multiple organ injury,especially acute respiratory distress syndrome(ARDS),contributing to a high mortality of the disease[1,2].More evidence showed that corticosteroid,an immunomodulatory agent,reduces both the need of invasive mechanical ventilation and lowers the mortality of severe COVID-19 patients.However,its optimal dose and therapeutic duration is still ambiguous.The RECOVERY trial revealed that using corticosteroid up to 10 days reduced the mortality of hospitalized COVID-19 patients[3]and a finding also upheld by a meta-analysis by Cano et al.[4].To the best of our knowledge,currently,there is no study evaluating disease progression after discontinuation of corticosteroid treatment in COVID-19 patients with ARDS.

关 键 词：MORTALITY ACUTE DISTRESS 

分 类 号：R563.1[医药卫生—呼吸系统]